Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients

Wang, Shuai; Han, Xiaohong; Hu, Xingsheng; Wang, Xiaoyuan; Zhao, Lingdi; Tang, Le; Feng, Yun; Wu, Di; Sun, Yan; Shi, Yuankai

doi:10.1016/j.cca.2013.12.026

Cited by 44 publications

(41 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total number of patients included in this study was 2518, ranging from 22 [21, 37] to 446 [29] cases per study. 12 studies evaluated the prognostic role of cfDNA concentration in NSCLC [9, 19–22, 27–33]. 4 studies reported the prognostic role of KRAS genotype detected in cfDNA for NSCLC [20, 23, 25, 34]].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Liu

Huang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Circulating cell-free DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response and survival for cancer patients. Several studies have assessed the prognostic and predictive value of cfDNA in non-small cell lung cancer (NSCLC). However, these studies were often small and reported varying results. To address this issue, a meta-analysis was carried out. A total of 22 studies involving 2518 patients were subjected to the final analysis. Our results indicated that NSCLC patients with higher cfDNA concentration had shorter median progression-free survival (PFS) and overall survival (OS) time. In addition, high levels of cfDNA were significantly associated with poor PFS (hazard ratio or HR, 1.32; 95% CI, 1.02-1.71) and OS (HR, 1.64; 95% CI, 1.26-2.15). With respect to tumor specific mutations, we failed to reveal significant differences for PFS (HR, 1.30; 95% CI, 0.66-2.56) and OS (HR, 1.05; 95% CI, 0.49-2.25) when NSCLC patients were grouped according to KRAS genotype detected in cfDNA. However, NSCLC patients which harbored EGFR activating mutation in cfDNA had a greater chance of response to EGFR-TKIs (odds ratio or OR, 1.96; 95% CI, 1.59-2.42). No significant publication bias was detected in this study. In conclusion, cfDNA could act as a prognostic and predictive biomarker for patients with NSCLC.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Six studies reported the median progression-free survival (PFS) time in NSCLC patients according to different cfDNA concentrations (high or low) [19, 20, 27, 29, 30, 32]. As showed in Figure 2A, patients with high levels of cfDNA usually had shorter PFS time than those with low cfDNA concentrations.…”

Section: Resultsmentioning

confidence: 99%

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Liu

Huang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…It has been documented that EGFR mutation status is a sensitive and reliable biomarker for EGFRTKIs therapy (3,4). Patients carrying the point mutation in exon 21 (L858R) or deletion in exon 19 show good response to EGFRTKIs (4); on the other hand, the point mutation (T790M) in exon20 indicates resistance to EGFR-TKIs and poor prognosis (5). It has also been reported that EGFR mutation status might change after chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Many studies have shown the feasibility and predictive value of using ctDNA to monitor tumor dynamics in various solid tumors (14)(15)(16)(17), in which ctDNA even showed better test performance than circulating tumor cells and conventional serum biomarkers (18). As for NSCLC, many clinical centers have investigated the diagnostic accuracy of ctDNA for detection of EGFR mutation (19)(20)(21). The concordance rate of EGFR mutation between ctDNA and tumor tissues is largely dependent on detection techniques, and varies from 66% to 100% (22).…”

Section: Introductionmentioning

confidence: 99%

Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

Qiu

Wang

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

163

114

View full text Add to dashboard Cite

Background: Circulating tumor DNA (ctDNA) has offered a minimally invasive and feasible approach for detection of EGFR mutation for non-small cell lung cancer (NSCLC). This meta-analysis was designed to investigate the diagnostic value of ctDNA, compared with current "gold standard," tumor tissues.Methods: We searched PubMed, EMBASE, Cochrane Library, and Web of Science to identify eligible studies that reported the sensitivity and specificity of ctDNA for detection of EGFR mutation status in NSCLC. Eligible studies were pooled to calculate the pooled sensitivity, specificity, and diagnostic odds ratio (DOR). The summary ROC curve (SROC) and area under SROC (AUS-ROC) were used to evaluate the overall diagnostic performance.

show abstract

“…Indeed, ctDNA can be a potential source of tumor DNA alteration pursuing for the documentation of tumor-associated genetic changes in order to real-time tumor monitoring [4,53,78,79]. For NonSmall Cell Lung Cancer Research (NSCLC), numerous clinical centers have investigated the diagnostic precision of ctDNA for EGFR mutation detection [80][81][82][83]. In 2016 the U.S. Food and Drug Administration (FDA) agreed to the EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (Erlotinib) [84].…”

Section: Lung Cancermentioning

confidence: 99%

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Khatami

Tavangar

2018

J Diabetes Metab Disord

View full text Add to dashboard Cite

The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive, preventive, personalized, and Participatory (P4) medicine for cancer managements. In fact tumor heterogeneity is a central part of cancer evolution,soin order to progress in understanding of the dynamics within a tumor some diagnostic apparatus should be improved. Latest molecular techniques like Next generation Sequencing (NGS) and ultra-deep sequencing could disclose some clones within a liquid tumor biopsy which mainly responsible of treatment resistance. Circulating tumor DNA (ctDNA) as a main component of liquid biopsy is agifted biomarker for cancer mutation tracking as well as profiling. Personalized medicine facilitate learning regarding to genetic pools of tumor and their possible respond to treatment which could be much easier by using of ctDNA.With this information, cliniciansarelooking forward to find the best strategies for prevention, screening, and treatment in the way of precision medicine. Currently, numerous clinical efficacy of such informative improved treatment are in hand. Here we represent the review of plasma-derived ctDNA studies use in personalized cancer managements.

show abstract

Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients

Cited by 44 publications

References 23 publications

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Contact Info

Product

Resources

About